You are here

lecanemab

FDA sets July decision date for full approval of Leqembi

FDA sets July decision date for full approval of Leqembi

BioSpace

Alzheimer's disease

Flag link:

Eisai Anticipates Full Approval of Leqembi as Early as July

Eisai Anticipates Full Approval of Leqembi as Early as July

BioSpace

Alzheimer's disease

Flag link:

Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval

Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval

Motley Fool

Alzheimer's disease

Flag link:

New Biogen CEO tips subcutaneous lecanemab to help expansion into pre-symptomatic Alzheimer’s

New Biogen CEO tips subcutaneous lecanemab to help expansion into pre-symptomatic Alzheimer’s

Fierce Pharma

Chris Viehbacher

Alzheimer's disease

Flag link:

Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?

Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?

Clinical Trials Arena

clinical trials

Alzheimer's disease

Flag link:

After FDA nod, Eisai and Biogen file lecanemab in EU

After FDA nod, Eisai and Biogen file lecanemab in EU

Pharmaphorum

Alzheimer's disease

Flag link:

Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

BioPharma Dive

Alzheimer's disease

Flag link:

FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision

FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision

BioPharma Dive

Alzheimer's disease

Flag link:

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Stat

Alzheimer's disease

Flag link:

3rd patient death potentially tied to Eisai's Alzheimer's drug reported

3rd patient death potentially tied to Eisai's Alzheimer's drug reported

Fierce Biotech

Alzheimer's disease

clinical trials

Flag link:

CTAD 2022 – lecanemab data hold up, with a big but

CTAD 2022 – lecanemab data hold up, with a big but

EP Vantage

Alzheimer's disease

clinical trials

Flag link:

What to make of Eisai and Biogen’s latest Alzheimer’s drug data

What to make of Eisai and Biogen’s latest Alzheimer’s drug data

BioPharma Dive

Alzheimer's disease

Flag link:

Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal

Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal

Fierce Biotech

clinical trials

Alzheimer's disease

Flag link:

Lilly powers through final stretch in critical Alzheimer's race

Lilly powers through final stretch in critical Alzheimer's race

Fierce Biotech

Alzheimer's disease

Flag link:

Eisai's Alzheimer's hopeful lecanemab may have contributed to patient death: report

Eisai's Alzheimer's hopeful lecanemab may have contributed to patient death: report

Fierce Biotech

Alzheimer's disease

clinical trials

Flag link:

Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates

Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates

Endpoints

Alzheimer's disease

Flag link:

Where Will Biogen Be in 5 Years?

Where Will Biogen Be in 5 Years?

Motley Fool

Alzheimer's disease

Flag link:

Roche CEO Cautious on Alzheimer’s Trial Despite Eisai’s Success

Roche CEO Cautious on Alzheimer’s Trial Despite Eisai’s Success

Bloomberg

Alzheimer's disease

Flag link:

4 Biotech Stocks With Huge Incoming Catalysts

4 Biotech Stocks With Huge Incoming Catalysts

Motley Fool

Alzheimer's disease

Gilead Sciences

Mirati Therapeutics

Flag link:

Lecanemab can; now the wait for details begins

Lecanemab can; now the wait for details begins

EP Vantage

clinical trials

Alzheimer's disease

Flag link:

Pages